Navigation Links
New Study Provides Key Findings for Biopharma Product Launch Evaluation

CHAPEL HILL, N.C., Nov. 5 /PRNewswire/ -- As biopharmaceutical companies continue to bring new therapies to market, considerable efforts are placed on strategy and execution from development through launch, while post-launch evaluations largely focus on revenue growth and little else. In a continuing effort to support product launch excellence, a recent study was conducted by Best Practices, LLC reviewing launch evaluation with insights available in the newly published report, "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success." This research initiative explored excellence in launch evaluation yielding key findings into continuous improvement strategies, plans and practices for both current and future landscapes across the biopharmaceutical industry.

To view the study abstract or complimentary summary of the full report "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success," click on the following link

In a benchmarking study that included such influential companies as Abbott, GlaxoSmithKline, Novo Nordisk, Roche, and Sanofi-Aventis, many key topics were covered, including:
-- Understand Product Launch Evaluation Process

-- Determine Role of Forecasting in Evaluating Success

-- Identify Key Performance Measures Used

-- Review Importance of Specific Launch Evaluation Performance Measures

-- Describe Process and Timetable for Recalibration of Launch Targets

For more information on this report, contact Robert Naylor at or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to


Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
2. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
3. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
4. Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. Large-scale genetic study sheds new light on lung cancer
7. PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
8. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
9. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
10. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
11. eRT Completes Milestone 100th Thorough QT Study
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
Breaking Biology Technology:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 /PRNewswire/ ... innovator in modern authentication and a founding member of ... of its latest version of the Nok Nok™ S3 ... use standards-based authentication that supports existing and emerging methods ... is ideal for organizations deploying customer-facing applications that require ...
Breaking Biology News(10 mins):